LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,089
تعداد مقالات9,999
تعداد مشاهده مقاله26,675,058
تعداد دریافت فایل اصل مقاله7,330,714
Ajdari, Mohammadreza, Ranjbar, Aliyeh, Karimian, Khashayar, Karimi, Maryam, Heli, Hossein, Sattarahmady, Naghmeh. (1403). Characterization and Evaluation of Nano-niosomes Encapsulating Docetaxel against Human Breast, Pancreatic, and Pulmonary Adenocarcinoma Cancer Cell Lines. سامانه مدیریت نشریات علمی, 14(2), 159-168. doi: 10.31661/jbpe.v0i0.2401-1708
Mohammadreza Ajdari; Aliyeh Ranjbar; Khashayar Karimian; Maryam Karimi; Hossein Heli; Naghmeh Sattarahmady. "Characterization and Evaluation of Nano-niosomes Encapsulating Docetaxel against Human Breast, Pancreatic, and Pulmonary Adenocarcinoma Cancer Cell Lines". سامانه مدیریت نشریات علمی, 14, 2, 1403, 159-168. doi: 10.31661/jbpe.v0i0.2401-1708
Ajdari, Mohammadreza, Ranjbar, Aliyeh, Karimian, Khashayar, Karimi, Maryam, Heli, Hossein, Sattarahmady, Naghmeh. (1403). 'Characterization and Evaluation of Nano-niosomes Encapsulating Docetaxel against Human Breast, Pancreatic, and Pulmonary Adenocarcinoma Cancer Cell Lines', سامانه مدیریت نشریات علمی, 14(2), pp. 159-168. doi: 10.31661/jbpe.v0i0.2401-1708
Ajdari, Mohammadreza, Ranjbar, Aliyeh, Karimian, Khashayar, Karimi, Maryam, Heli, Hossein, Sattarahmady, Naghmeh. Characterization and Evaluation of Nano-niosomes Encapsulating Docetaxel against Human Breast, Pancreatic, and Pulmonary Adenocarcinoma Cancer Cell Lines. سامانه مدیریت نشریات علمی, 1403; 14(2): 159-168. doi: 10.31661/jbpe.v0i0.2401-1708

Characterization and Evaluation of Nano-niosomes Encapsulating Docetaxel against Human Breast, Pancreatic, and Pulmonary Adenocarcinoma Cancer Cell Lines

Journal of Biomedical Physics and Engineering
دوره 14، شماره 2، تیر 2024، صفحه 159-168    اصل مقاله (885.06 K)
نوع مقاله: Original Research
شناسه دیجیتال (DOI): 10.31661/jbpe.v0i0.2401-1708
نویسندگان
Mohammadreza Ajdari1؛ Aliyeh Ranjbar1؛ Khashayar Karimian2؛ Maryam Karimi1؛ Hossein Heli1؛ Naghmeh Sattarahmady* 1، 3
1Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2Arasto Pharmaceutical Chemicals Inc., Yousefabad, Jahanarar Avenue, Tehran, Iran
3Department of Medical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: Docetaxel (DXL) is an antineoplastic agent for cancer treatment, the therapeutic efficiency of which is limited due to low solubility, hydrophobicity, and tissue specificity.
Objective: In this study, nano-niosomes were introduced for improving therapeutic index of DXL.
Material and Methods: In this experimental study, two nano-niosomes were synthesized using Span 20® and Span 80® and a thin film hydration method with DXL loading (DXL-Span20 and DXL-Span80). Characterization, in-vitro cytotoxicity and bioavailability of the nano-niosomes was also evaluated via in-vivo experiments.
Results: DXL-Span20 and DXL-Span80 have vesicles size in a range of 84-90 nm and negative zeta potentials. DXL entrapment efficiencies were obtained as 69.6 and 74.0% for DXL-Span20 and DXL-Span80, respectively; with an in-vitro sustained release patterns. Cytotoxicity assays were performed against MDA-MB-231, Calu-6, and AsPC-1 cell lines, and the results indicated that DXL loading into nano-niosomes led to decrement in values of half-maximal inhibitory concentration (IC50) at least 2.5 times and at most 6.5 times, compared to free DXL. Moreover, the rat blood bioavailability of DXL after intraperitoneal administration and the pharmacokinetic parameters indicated higher DXL plasma level and the higher effectiveness of DXL-Span80 compared to DXL-Span20. 
Conclusion: Carrying DXL by the nano-niosomes led to enhanced cytotoxicity (and lower IC50 values) and higher efficacy with enhanced pharmacokinetic parameters.

تازه های تحقیق

Naghmeh Sattarahmady (Google Scholar)

کلیدواژه‌ها
Docetaxel؛ Taxane؛ Taxotere®؛ Niosome؛ Sorbitan Monolaurate؛ Drug Delivery Systems
سایر فایل های مرتبط با مقاله
مراجع
  1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177-93. doi: 10.3322/caac.21395. PubMed PMID: 28248415.
  2. Kemp JA, Kwon YJ. Cancer nanotechnology: current status and perspectives. Nano Converg. 2021;8(1):34. doi: 10.1186/s40580-021-00282-7. PubMed PMID: 34727233. PubMed PMCID: PMC8560887.
  3. Karimi M, Karimian K, Heli H. A nanoemulsion-based delivery system for imatinib and in vitro anticancer efficacy. Braz J Pharm Sci. 2020;56:e18973. doi: 10.1590/s2175-97902020000118973.
  4. Negahdary M, Sattarahmady N, Heli H. Advances in prostate specific antigen biosensors-impact of nanotechnology. Clin Chim Acta. 2020;504:43-55. doi: 10.1016/j.cca.2020.01.028. PubMed PMID: 32004532.
  5. Dehdari Vais R, Heli H, Sattarahmady N. Label-free electrochemical DNA biosensing of MR TV 29 18s ribosomal RNA gene of Trichomonas vaginalis by signalization of non-spherical gold nanoparticles. J Mater Today Commun. 2023;34:105123. doi: 10.1016/j.mtcomm.2022.105123.
  6. Ilbeigi S, Ranjbar A, Zahraie N, Dehdari Vais R, Monjezi MR, Sattarahmady N. Sonodynamic therapy of pancreatic cancer cells based on synergistic chemotherapeutic effects of selenium-PEG-curcumin nanoparticles and gemcitabine. J Appl Phys A. 2023;129(2):82. doi: 10.1007/s00339-022-06377-0.
  7. Zahraie N, Haghighi H, Salehi F, Daneshvar F, Tamaddon P, Sattarahmady N. Pulsed sonodynamic therapy of melanoma cancer cells using nanoparticles of and mesoporous platinum. Ultrasound Med Biol. 2023;49(9):2160-8. doi: 10.1016/j.ultrasmedbio.2023.06.011. PubMed PMID: 37414634.
  8. Kayani Z, Islami N, Behzadpour N, Zahraie N, Imanlou S, Tamaddon P, et al. Combating cancer by utilizing noble metallic nanostructures in combination with laser photothermal and X-ray radiotherapy. J Drug Deliv Sci Technol. 2021;65:102689. doi: 10.1016/j.jddst.2021.102689
  9. Perota G, Faghani-Eskandarkolaei P, Zahraie N, Zare MH, Sattarahmady N. A Study of Sonodynamic Therapy of Melanoma C540 Cells in Vitro by Titania/Gold Nanoparticles. J Biomed Phys Eng. 2024;14(1):43-54. doi: 10.31661/jbpe.v0i0.2310-1674. PubMed PMID: 38357599. PubMed PMCID: PMC10862114.
  10. Sharma CP. Drug Delivery Nanosystems for Biomedical Applications. Elsevier; 2018.
  11. Heli H, Mirtorabi S, Karimian K. Advances in iron chelation: an update. Expert Opin Ther Pat. 2011;21(6):819-56. doi: 10.1517/13543776.2011.569493. PubMed PMID: 21449664.
  12. Negahdary M, Heli H. Applications of Nanoflowers in Biomedicine. Recent Pat Nanotechnol. 2018;12(1):22-33. doi: 10.2174/1872210511666170911153428. PubMed PMID: 28901846.
  13. Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Control Release. 2014;185:22-36. doi: 10.1016/j.jconrel.2014.04.015. PubMed PMID: 24747765.
  14. Bashkeran T, Kamaruddin AH, Ngo TX, Suda K, Umakoshi H, Watanabe N, Nadzir MM. Niosomes in cancer treatment: A focus on curcumin encapsulation. 2023;9(8):e18710. doi: 10.1016/j.heliyon.2023.e18710. PubMed PMID: 37593605. PubMed PMCID: PMC10428065.
  15. Ramaswamy B, Puhalla S. Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors. Drugs Today (Barc). 2006;42(4):265-79. doi: 10.1358/dot.2006.42.4.968648. PubMed PMID: 16703123.
  16. Ganesh T. Improved biochemical strategies for targeted delivery of taxoids. Bioorg Med Chem. 2007;15(11):3597-623. doi: 10.1016/j.bmc.2007.03.041. PubMed PMID: 17419065. PubMed PMCID: PMC2374751.
  17. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, André S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol. 1995;22(2 Suppl 4):3-16. PubMed PMID: 7740328.
  18. Aapro M, Bruno R. Early clinical studies with docetaxel. Docetaxel Investigators Group. Eur J Cancer. 1995;31A(Suppl 4):S7-10. doi: 10.1016/0959-8049(95)00360-u. PubMed PMID: 7577102.
  19. Saloustros E, Georgoulias V. Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2008;8(8):1207-22. doi: 10.1586/14737140.8.8.1207. PubMed PMID: 18699760.
  20. Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview. Eur J Cancer. 1997;33(13):2167-70. doi: 10.1016/s0959-8049(97)00363-8. PubMed PMID: 9470802.
  21. Engels FK, Sparreboom A, Mathot RA, Verweij J. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br J Cancer. 2005;93(2):173-7. doi: 10.1038/sj.bjc.6602698. PubMed PMID: 16012521. PubMed PMCID: PMC2361544.
  22. Ren G, Liu D, Guo W, Wang M, Wu C, Guo M, et al. Docetaxel prodrug liposomes for tumor therapy: characterization, in vitro and in vivo evaluation. Drug Deliv. 2016;23(4):1272-81. doi: 10.3109/10717544.2016.1165312. PubMed PMID: 26965023.
  23. Syrigou E, Dannos I, Kotteas E, Makrilia N, Tourkantonis I, Dilana K, et al. Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol. 2011;156(3):320-4. doi: 10.1159/000324454. PubMed PMID: 21720178.
  24. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006;24(10):1633-42. doi: 10.1200/JCO.2005.04.0543. PubMed PMID: 16575015.
  25. Ho MY, Mackey JR. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res. 2014;6:253-9. doi: 10.2147/CMAR.S40601. PubMed PMID: 24904223. PubMed PMCID: PMC4041377.
  26. Garrido-Siles M, Arenas-Villafranca JJ, Pérez-Ruiz E, De Linares Fernández MF, Tortajada B, Rivas-Ruiz F, et al. New cutaneous toxicities with generic docetaxel: are the excipients guilty? Support Care Cancer. 2015;23(7):1917-23. doi: 10.1007/s00520-014-2499-2. PubMed PMID: 25487841.
  27. Can G, Aydiner A, Cavdar I. Taxane-induced nail changes: Predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity. Eur J Oncol Nurs. 2012;16(3):270-5. doi: 10.1016/j.ejon.2011.06.007. PubMed PMID: 21784705.
  28. Mark M, Walter R, Meredith DO, Reinhart WH. Commercial taxane formulations induce stomatocytosis and increase blood viscosity. Br J Pharmacol. 2001;134(6):1207-14. doi: 10.1038/sj.bjp.0704387. PubMed PMID: 11704640. PubMed PMCID: PMC1573070.
  29. Pardakhty A, Moazeni E. Nano-niosomes in drug, vaccine and gene delivery: a rapid overview. Nanomed J. 2013;1(1):1-12. doi: 10.22038/NMJ.2013.697.
  30. Xin Y, Yin M, Zhao L, Meng F, Luo L. Recent progress on nanoparticle-based drug delivery systems for cancer therapy. Cancer Biol Med. 2017;14(3):228-41. doi: 10.20892/j.issn.2095-3941.2017.0052. PubMed PMID: 28884040. PubMed PMCID: PMC5570600.
  31. Jain S, Jain V, Mahajan SC. Lipid based vesicular drug delivery systems. Advances in Pharmaceutics. 2014:574673. doi: 10.1155/2014/574673.
  32. Sezgin-Bayindir Z, Yuksel N. Investigation of formulation variables and excipient interaction on the production of niosomes. AAPS PharmSciTech. 2012;13(3):826-35. doi: 10.1208/s12249-012-9805-4. PubMed PMID: 22644706. PubMed PMCID: PMC3429677.
  33. Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery—an overview. Acta Pharm Sin B. 2011;1(4):208-19. doi: 10.1016/j.apsb.2011.09.002.
  34. Ag Seleci D, Seleci M, Walter JG, Stahl F, Scheper T. Niosomes as nanoparticular drug carriers: fundamentals and recent applications. J Nanomater. 2016:7372306. doi: 10.1155/2016/7372306.
  35. Verma S, Singh SK, Syan N, Mathur P, Valecha V. Nanoparticle vesicular systems: a versatile tool for drug delivery. J Chem Pharm Res. 2010;2(2):496-509.
  36. Azeem A, Anwer MK, Talegaonkar S. Niosomes in sustained and targeted drug delivery: some recent advances. J Drug Target. 2009;17(9):671-89. doi: 10.3109/10611860903079454. PubMed PMID: 19845484.
  37. Kenicer J, Spears M, Lyttle N, Taylor KJ, Liao L, Cunningham CA, et al. Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance. BMC Cancer. 2014;14:762. doi: 10.1186/1471-2407-14-762. PubMed PMID: 25312014. PubMed PMCID: PMC4203938.
  38. Majidi M, Safaee S, Amini M, Baghbanzadeh A, Hajiasgharzadeh K, Hashemzadeh S, et al. The effects of chemotherapeutic drugs on PD-L1 gene expression in breast cancer cell lines. Med Oncol. 2021;38(12):147. doi: 10.1007/s12032-021-01556-0. PubMed PMID: 34687372.
آمار
تعداد مشاهده مقاله: 15,514
تعداد دریافت فایل اصل مقاله: 71


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب